425 related articles for article (PubMed ID: 25986460)
41. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
Julian-Reynier C; Mancini J; Mouret-Fourme E; Gauthier-Villars M; Bonadona V; Berthet P; Fricker JP; Caron O; Luporsi E; Noguès C
Eur J Hum Genet; 2011 May; 19(5):500-6. PubMed ID: 21267012
[TBL] [Abstract][Full Text] [Related]
42. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
43. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
[TBL] [Abstract][Full Text] [Related]
44. Mammographic density, MRI background parenchymal enhancement and breast cancer risk.
Pike MC; Pearce CL
Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii37-viii41. PubMed ID: 24131968
[TBL] [Abstract][Full Text] [Related]
45. MRI volumetric analysis of breast fibroglandular tissue to assess risk of the spared nipple in BRCA1 and BRCA2 mutation carriers.
Baltzer HL; Alonzo-Proulx O; Mainprize JG; Yaffe MJ; Metcalfe KA; Narod SA; Warner E; Semple JL
Ann Surg Oncol; 2014 May; 21(5):1583-8. PubMed ID: 24526546
[TBL] [Abstract][Full Text] [Related]
46. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
47. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
Sherman ME; Piedmonte M; Mai PL; Ioffe OB; Ronnett BM; Van Le L; Ivanov I; Bell MC; Blank SV; DiSilvestro P; Hamilton CA; Tewari KS; Wakeley K; Kauff ND; Yamada SD; Rodriguez G; Skates SJ; Alberts DS; Walker JL; Minasian L; Lu K; Greene MH
J Clin Oncol; 2014 Oct; 32(29):3275-83. PubMed ID: 25199754
[TBL] [Abstract][Full Text] [Related]
48. DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence.
Wu S; Zuley ML; Berg WA; Kurland BF; Jankowitz RC; Sumkin JH; Gur D
Sci Rep; 2017 May; 7(1):2115. PubMed ID: 28522877
[TBL] [Abstract][Full Text] [Related]
49. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
50. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
51. Decision-making for Risk-reducing Salpingo-oophorectomy (RRSO) in Southeast Asian BRCA Mutation Carriers With Breast Cancer: A Qualitative Study.
Sa'at H; Lee YK; Yoon SY; Wong SW; Woo YL; Barlow-Stewart K; Mohd Taib NA
Int J Behav Med; 2022 Feb; 29(1):1-13. PubMed ID: 33791992
[TBL] [Abstract][Full Text] [Related]
52. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
[TBL] [Abstract][Full Text] [Related]
53. Generalizable attention U-Net for segmentation of fibroglandular tissue and background parenchymal enhancement in breast DCE-MRI.
Nowakowska S; Borkowski K; Ruppert CM; Landsmann A; Marcon M; Berger N; Boss A; Ciritsis A; Rossi C
Insights Imaging; 2023 Nov; 14(1):185. PubMed ID: 37932462
[TBL] [Abstract][Full Text] [Related]
54. Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
Sung JS; Corben AD; Brooks JD; Edelweiss M; Keating DM; Lin C; Morris EA; Patel P; Robson M; Woods M; Bernstein JL; Pike MC
Breast Cancer Res Treat; 2018 Nov; 172(2):487-496. PubMed ID: 30140962
[TBL] [Abstract][Full Text] [Related]
55. Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?
Dontchos BN; Rahbar H; Partridge SC; Korde LA; Lam DL; Scheel JR; Peacock S; Lehman CD
Radiology; 2015 Aug; 276(2):371-80. PubMed ID: 25965809
[TBL] [Abstract][Full Text] [Related]
56. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Shu CA; Pike MC; Jotwani AR; Friebel TM; Soslow RA; Levine DA; Nathanson KL; Konner JA; Arnold AG; Bogomolniy F; Dao F; Olvera N; Bancroft EK; Goldfrank DJ; Stadler ZK; Robson ME; Brown CL; Leitao MM; Abu-Rustum NR; Aghajanian CA; Blum JL; Neuhausen SL; Garber JE; Daly MB; Isaacs C; Eeles RA; Ganz PA; Barakat RR; Offit K; Domchek SM; Rebbeck TR; Kauff ND
JAMA Oncol; 2016 Nov; 2(11):1434-1440. PubMed ID: 27367496
[TBL] [Abstract][Full Text] [Related]
57. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
Cohen JV; Chiel L; Boghossian L; Jones M; Stopfer JE; Powers J; Rebbeck TR; Nathanson KL; Domchek SM
Fam Cancer; 2012 Mar; 11(1):69-75. PubMed ID: 21898151
[TBL] [Abstract][Full Text] [Related]
58. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
[TBL] [Abstract][Full Text] [Related]
59. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
Michelsen TM; Dørum A; Dahl AA
Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
[TBL] [Abstract][Full Text] [Related]
60. Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis.
Lewin AA; Kim SG; Babb JS; Melsaether AN; McKellop J; Moccaldi M; Klautau Leite AP; Moy L
Acad Radiol; 2016 Mar; 23(3):358-67. PubMed ID: 26774741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
